PROCESSA PHARMACEUTICALS INC (PCSA) Stock Fundamental Analysis

NASDAQ:PCSA • US74275C4033

2.45 USD
+0.12 (+5.15%)
At close: Feb 11, 2026
2.46 USD
+0.01 (+0.41%)
Pre-Market: 2/12/2026, 8:40:34 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

PCSA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. PCSA has a great financial health rating, but its profitability evaluates not so good. PCSA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • PCSA had negative earnings in the past year.
  • PCSA had a negative operating cash flow in the past year.
  • PCSA had negative earnings in each of the past 5 years.
  • In the past 5 years PCSA always reported negative operating cash flow.
PCSA Yearly Net Income VS EBIT VS OCF VS FCFPCSA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

  • With a Return On Assets value of -170.52%, PCSA is not doing good in the industry: 87.96% of the companies in the same industry are doing better.
  • PCSA's Return On Equity of -221.71% is on the low side compared to the rest of the industry. PCSA is outperformed by 74.35% of its industry peers.
Industry RankSector Rank
ROA -170.52%
ROE -221.71%
ROIC N/A
ROA(3y)-293.98%
ROA(5y)-200.12%
ROE(3y)-432.49%
ROE(5y)-285.06%
ROIC(3y)N/A
ROIC(5y)N/A
PCSA Yearly ROA, ROE, ROICPCSA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

1.3 Margins

  • PCSA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PCSA Yearly Profit, Operating, Gross MarginsPCSA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • Compared to 1 year ago, PCSA has more shares outstanding
  • PCSA has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, PCSA has a worse debt to assets ratio.
PCSA Yearly Shares OutstandingPCSA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M
PCSA Yearly Total Debt VS Total AssetsPCSA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

2.2 Solvency

  • PCSA has an Altman-Z score of 24.67. This indicates that PCSA is financially healthy and has little risk of bankruptcy at the moment.
  • PCSA's Altman-Z score of 24.67 is amongst the best of the industry. PCSA outperforms 89.53% of its industry peers.
  • PCSA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 24.67
ROIC/WACCN/A
WACCN/A
PCSA Yearly LT Debt VS Equity VS FCFPCSA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M 20M

2.3 Liquidity

  • A Current Ratio of 3.76 indicates that PCSA has no problem at all paying its short term obligations.
  • PCSA has a Current ratio (3.76) which is comparable to the rest of the industry.
  • A Quick Ratio of 3.76 indicates that PCSA has no problem at all paying its short term obligations.
  • With a Quick ratio value of 3.76, PCSA perfoms like the industry average, outperforming 59.16% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.76
Quick Ratio 3.76
PCSA Yearly Current Assets VS Current LiabilitesPCSA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 71.96% over the past year.
EPS 1Y (TTM)71.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%93.2%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 18.72% on average over the next years. This is quite good.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y88.99%
EPS Next 2Y39.6%
EPS Next 3Y24.83%
EPS Next 5Y18.72%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PCSA Yearly Revenue VS EstimatesPCSA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2027 2M 4M 6M
PCSA Yearly EPS VS EstimatesPCSA Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -200 -400 -600

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • PCSA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PCSA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PCSA Price Earnings VS Forward Price EarningsPCSA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PCSA Per share dataPCSA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30

4.3 Compensation for Growth

  • A more expensive valuation may be justified as PCSA's earnings are expected to grow with 24.83% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.6%
EPS Next 3Y24.83%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • PCSA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PROCESSA PHARMACEUTICALS INC

NASDAQ:PCSA (2/11/2026, 8:00:00 PM)

Premarket: 2.46 +0.01 (+0.41%)

2.45

+0.12 (+5.15%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06
Earnings (Next)03-18
Inst Owners3.14%
Inst Owner Change-14.15%
Ins Owners0.82%
Ins Owner Change0%
Market Cap138.77M
Revenue(TTM)N/A
Net Income(TTM)-12.93M
Analysts80
Price Target25.5 (940.82%)
Short Float %N/A
Short Ratio0.02
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.83%
Min EPS beat(2)-6.56%
Max EPS beat(2)14.22%
EPS beat(4)3
Avg EPS beat(4)22.65%
Min EPS beat(4)-6.56%
Max EPS beat(4)61.8%
EPS beat(8)4
Avg EPS beat(8)11.52%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)2400%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1864.29%
EPS NY rev (1m)0%
EPS NY rev (3m)-2233.33%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 23.79
P/tB 23.79
EV/EBITDA N/A
EPS(TTM)-34
EYN/A
EPS(NY)-4.97
Fwd EYN/A
FCF(TTM)-0.19
FCFYN/A
OCF(TTM)-0.19
OCFYN/A
SpS0
BVpS0.1
TBVpS0.1
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -170.52%
ROE -221.71%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-293.98%
ROA(5y)-200.12%
ROE(3y)-432.49%
ROE(5y)-285.06%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.76
Quick Ratio 3.76
Altman-Z 24.67
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)71.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%93.2%
EPS Next Y88.99%
EPS Next 2Y39.6%
EPS Next 3Y24.83%
EPS Next 5Y18.72%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-10.5%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-27.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-27.21%
OCF growth 3YN/A
OCF growth 5YN/A

PROCESSA PHARMACEUTICALS INC / PCSA FAQ

What is the fundamental rating for PCSA stock?

ChartMill assigns a fundamental rating of 2 / 10 to PCSA.


Can you provide the valuation status for PROCESSA PHARMACEUTICALS INC?

ChartMill assigns a valuation rating of 1 / 10 to PROCESSA PHARMACEUTICALS INC (PCSA). This can be considered as Overvalued.


How profitable is PROCESSA PHARMACEUTICALS INC (PCSA) stock?

PROCESSA PHARMACEUTICALS INC (PCSA) has a profitability rating of 0 / 10.


What is the expected EPS growth for PROCESSA PHARMACEUTICALS INC (PCSA) stock?

The Earnings per Share (EPS) of PROCESSA PHARMACEUTICALS INC (PCSA) is expected to grow by 88.99% in the next year.